New cancer drug MT-4561 enters first human tests

NCT ID NCT06943521

Recruiting now Disease control Sponsor: Tanabe Pharma America, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human study, so the drug's effects and risks are still unknown.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MT-4561 (given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early first-in-human trial with only 27 participants. The drug may not shrink tumors or could cause serious side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms breast cancer breast neoplasm carcinoma cervical cancer endometrial cancer endometrium neoplasm esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm head and neck squamous cell carcinoma neuroendocrine carcinoma neuroendocrine neoplasm non-small cell lung carcinoma ovarian cancer pancreatic ductal adenocarcinoma prostate cancer sarcoma soft tissue sarcoma Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma urothelial carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER BREAST CANCER CERVICAL CANCER ENDOMETRIAL CANCER ESOPHAGEAL CANCER GASTRIC CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) NEUROENDOCRINE CARCINOMA (NEC) NEUROENDOCRINE TUMOR (NET) NON-SMALL CELL LUNG CANCER (NSCLC) NUCLEAR PROTEIN IN TESTIS (NUT) CARCINOMA OVARIAN CANCER PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) PROSTATE CANCER SOFT TISSUE SARCOMA UROTHELIAL CARCINOMA

Contacts and locations

Locations

National Cancer Center Hospital
RECRUITING

Chuo-Ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

City, Japan
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Southern California
RECRUITING

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.